Skip to main content
Premium Trial:

Request an Annual Quote

Prudential Securities Begins Covering Genomics Sector

NEW YORK, Sept 22 – Prudential Securities said Friday it would begin analyst coverage of the genomics sector.

Charles Duncan, senior biotechnology analyst at the firm’s Prudential Vector Healthcare Group, will cover Celera Genomics (NYSE: CRA), CuraGen (Nasdaq: CRGN), Genome Therapeutics (Nasdaq: GENE), Human Genome Sciences (Nasdaq: HGSI), Myriad Genetics (Nasdaq: MYGN), Sangamo BioSciences (Nasdaq: SGMO), and Tularik (Nasdaq: TLRK).

Duncan, who holds a PhD in pharmaceutical sciences from the University of Colorado, initiated this coverage with the following recommendations:

Celera of Rockville, Md., was initiated with a 12-month target of $112. The genomic database company was up 12 3/8, or 14.5 percent, at 97 5/8 in afternoon trading.  

CuraGen of New Haven, Conn., was initiated with a 12-month target of $55. The genomics-based drug discovery company was up 7/16, or 1 percent, at 41 15/16.

Genome Therapeutics of Waltham, Mass., was initiated with a 12-month target of $25. The gene-based drug discovery company was up 1/4, or 1.3 percent, at 19 3/4.

Human Genome Sciences of Rockville, Md., was initiated with a 12-month target of $199. The gene-based drug discovery company was up 15 3/4, or 10.2 percent, at 169 15/16.

Myriad Genetics of Salt Lake City was initiated with a 12-month target of $89. The genetic variance screening company was up 3 9/16, or 5.6 percent, at 67 3/16.

Sangamo of Richmond, Calif., was initiated with a 12-month target of $56. The gene expression regulator company was down 1 1/16, or 2.34 percent, at 44 7/16.

Tularik of San Francisco was initiated with a 12-month target of $49. The gene-regulation drug developer was up 1/38, or 4.1 percent, at 34 7/8.

Duncan rated Myriad and Tularik each a strong buy and gave the others an accumulate rating.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.